Skip to main content

ACHV

Stock
Health Care
Biotechnology

Performance overview

ACHV Price
Price Chart

Forward-looking statistics

Beta
0.62
Risk
57.69%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

achieve life sciences is a specialty pharmaceutical company committed to advancing cytisine as a smoking cessation aid to overcome the global nicotine addiction epidemic.

Company info

SectorHealth Care
IndustryBiotechnology
Employees18
Market cap$182.7M

Fundamentals

Enterprise value$65.1M
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity96.90

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.35
Dividend per share
Revenue per share$0.00
Avg trading volume (30 day)$2M
Avg trading volume (10 day)$6M
Put-call ratio

Macro factor sensitivity

Growth+5.5
Credit+16.8
Liquidity-7.4
Inflation+2.5
Commodities+2.6
Interest Rates-0.9

Valuation

Dividend yield0.00%
PEG Ratio-1.90
Price to sales
P/E Ratio-1.90
Enterprise Value to Revenue
Price to book7.36

Upcoming events

Next earnings dayMay 13, 2025
Next dividend day
Ex. dividend day

News

Achieve Life Sciences Aces Pivotal Cytisinicline Study In Smoking Cessation

Achieve Life Sciences Inc (NASDAQ: ACHV) has announced positive topline results from the Phase 3 ORCA-2 trial of 3mg cytisinicline for 6-weeks or 12-weeks compared to a placebo in 810 adult smokers.  The 6- and 12-week cytisinicline treatments demonstrated significantly better.

Benzinga (April 27, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free